GATA6 and pancreatic adenocarcinoma: As demonstrated in Fig. 1J, K, low expression levels of GATA6-AS1 were primarily detected in individuals with advanced T and N stages in cohort A, and with the advanced N stage in cohort B. The further Kaplan–Meier survival analysis showed that low GATA6-AS1 expression was linked to the dismal OS of PDAC individuals from cohort A, cohort B, and TCGA-PAAD (Fig. 1L–N).